As this exciting new drug market continues to attract capital, investors are starting to ask about ways to invest in psychedelics.
The heightened potential recently attached to psychedelic drugs has made market players ask themselves how to invest in psychedelics.
The promising research associated with psychedelic medicine has generated interest in the potential for these products as treatments for mental health issues or even addiction to opioids.
Early projections for the space, including a data report from a Canadian exchange, have pegged the magic mushroom industry with the potential to reach a US$7 billion value by 2027.
The capital markets have opened the doors to this industry as a new wave of public companies pursues effective methods of medicine and product development to offer growth in this brand new arena.
Here the Investing News Network (INN) provides investors with a closer look at ways to invest in psychedelics, what to look for when starting in the space and the early trends seen so far in this nascent capital markets industry.
Ways to invest in psychedelics: Canadian markets offer early stage investment
As with the recent fast growth of the cannabis industry, the Canadian capital markets have welcomed the opportunity attached to psychedelics.
The Canadian space has already seen a significant number of public listings related to the psychedelic stocks market, as well as existing public businesses trying to get a piece of the pie.
The Canadian Securities Exchange (CSE) has long established itself as a hotbed for up-and-coming companies in growth-stage areas. It has been no different with psychedelics, and the exchange already offers a collection of stocks for investors to examine.
During an online video conversation, Richard Carleton, CEO of the CSE, said he’s held discussions with both companies and investors that are keenly interested in investment opportunities for the space.
The exchange executive stressed that investors need to keep an eye on the disclosures offered by companies operating businesses that may not be universally legal. This is something that the CSE got experience doing during the cannabis boom — the exchange began asking marijuana companies to fill out detailed forms indicating the risks associated with their businesses.
Carleton compared the two industries, saying while cannabis has raised millions of dollars in Canada to launch “the most exciting new consumer-packaged goods industry in generations,” the psychedelic stocks investment space is more akin to pharmaceuticals and takes a much more established medical approach to its business models.
A report put forth by the Toronto-based NEO Exchange shows nearly US$150 million was raised in the first half of 2020 for private-stage funding. The sum was raised by six names in the psychedelic space: COMPASS Pathways, Atai Life, Mind Medicine (MindMed) (NEO:MMED), Field Trip Psychedelics, Numinus (TSXV:NUMI) and Orthogonal Thinker.
MindMed and Numinus have already reached the public markets with flashy debuts in Canada.
“We are looking for like-minded investors who share our belief that new approaches and new ways of thinking are needed to supplement existing options,” Numinus CEO Payton Nyquvest said in a statement following the public launch of his firm.
Within the NEO, the opportunity attached to psychedelic stocks investment has been recognized as critical for the future of the up-and-coming Canadian exchange.
“The psychedelics space shows incredible promise and NEO is ready and willing to help bring that potential to fruition,” Jos Schmitt, president and CEO of the NEO, wrote in a letter attached to the exchange’s public report on psychedelic investments.
Ways to invest in psychedelics: Current investment landscape
As it stands, the investment arena for psychedelics offers an early stage entry for investors, with a crop of companies already trading with healthy volumes.
Currently investors are seeing brand new companies purely focused on the psychedelic business come out of the private stage and into the capital markets, as well as existing firms looking for assets or buying diversifying options with promising companies involved in psychedelics.
From the batch of new companies, the majority have put forward business models based on the psychedelic research of novel medicine, which like established pharmaceutical products will require heavy inspections and reviews.
The message of a pharmaceutical-like industry was echoed by the first major debut of a psychedelic firm on the NEO, MindMed.
JR Rahn, co-founder director and co-CEO of the firm, previously told INN his company is squarely focused on the medical aspect of the psychedelic drug industry.
MindMed reached the public markets as a way to raise capital in its pursuit for high-end medicine drug products aimed at treating opioid addiction.
“We don’t see a future in recreational psychedelics,” the MindMed executive said. “The only future that we see is psychedelics medicines being passed through the (US Food and Drug Administration).”
The wellness and improvement trend in the space is widespread, with the rest of the psychedelic drug investment stories relating to modern clinics offering novel treatments for people struggling with mental health issues. In design, these clinics offer a brand new method of treatment for patients.
During an online webinar, Dr. Michael Verbora, medical director with Field Trip Psychedelics, said the company’s flagship clinic in Toronto offers ketamine-assisted psychotherapy for depression, anxiety and in some instances even post-traumatic stress disorder (PTSD).
In February, Field Trip completed a private placement funding worth US$8.5 million.
Ronan Levy, executive chairman of Field Trip, credited the sum raised to a mixed array of international investment figures, such as academics and investment funds.
“(The investment) speaks profoundly to the level of interest, excitement and importance that people around the world are placing on the advancement of psychedelics and the role they may play in improving mental health, performance, general wellness and happiness.”
Ways to invest in psychedelics: Investor takeaway
The lofty expectations for the industry come as it has attached itself to the potential for becoming a go-to treatment available for patients dealing with mental health issues such as anxiety and depression; some even aspire to see it as an opioid addiction solution.
During his webinar, Verbora credited the interest in this space in part to a shift in the cultural acceptance and opinion of psychedelic medicine and psychedelic treatments.
This change has brought forth a particular excitement from the public markets, as well in terms of the investment opportunity attached to this sector.
Don’t forget to follow @INN_LifeScience for real-time updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: Numinus is a client of the Investing News Network. This article is not paid-for content.
The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.